Show simple item record

dc.contributor.authorDoshi, Peter
dc.contributor.authorJefferson, Tom
dc.date.accessioned2017-05-25T01:15:49Z
dc.date.available2017-05-25T01:15:49Z
dc.date.issued2015-03-02
dc.identifier.citationDoshi, P. & Jefferson, T. (2015). The evidence base for new drugs. BMJ, 350. DOI: 10.1136/bmj.h952
dc.identifier.urihttp://hdl.handle.net/10713/6606
dc.descriptionSubtitle: New legislation in Germany provides another piece of a complex puzzle; Editorial discussing Germany's "Pharmaceuticals Market Reorganisation Act" (AMNOG) and its effect on pharmaceutical clinical trial transparency
dc.description.urihttp://bmj.com/cgi/content/full/bmj.h952?ijkey=hRwGAL1FHmDsAe9&keytype=refen_US
dc.language.isoen_USen_US
dc.publisherBMJ Publishing Groupen_US
dc.subjectPharmaceuticals Market Reorganisation Acten_US
dc.subjectresearch transparencyen_US
dc.subject.lcshInstitut für Qualität und Wirtschaftlichkeit im Gesundheitswesenen_US
dc.subject.lcshSystematic reviews (Medical research)en_US
dc.subject.meshDrug Industry--legislation & jurisprudenceen_US
dc.titleThe evidence base for new drugsen_US
dc.typeArticleen_US
dc.identifier.doi10.1136/bmj.h952
dc.identifier.doi10.1136/bmj.h952
dc.identifier.pmid25731767
dc.description.urinameClick here for the free full-text article on publisher's websiteen_US
refterms.dateFOA2019-02-19T18:18:35Z


Files in this item

Thumbnail
Name:
Doshi_EvidenceBaseForNewDrugs_ ...
Size:
492.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record